Melanoma is a type of skin cancer with a very high malignancy. Before targeted drugs were available, patients with BRAF gene mutations indicated a poorer prognosis for melanoma. The mutation of the BRAF gene promotes the progression of melanoma. However, with the advancement of current clinical research, patients with melanoma having BRAF mutations have a better therapeutic effect with BRAF inhibitor targeted therapy. After adopting this targeted drug treatment, the cure rate has significantly increased, and the prognosis of patients has markedly improved. Therefore, patients with BRAF-mutated melanoma can benefit from targeted therapy.